EASD 2019 — PEX168 leads to sustained reductions of HbA1c in uncontrolled T2D


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Once-weekly treatment with polyethylene glycol loxenatide (PEX168), a new long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was associated with significant reductions in HbA1c compared with placebo in patients with type 2 diabetes (T2D) uncontrolled by metformin alone.

Why this matters

  • Metformin monotherapy may not adequately control glycemia in patients with T2D.

Study design

  • Patients with uncontrolled T2D (HbA1c, 7.0%-10.5%) were randomly assigned:
    • Metformin plus placebo (n=179).
    • Metformin plus PEX168 100 μg (n=179).
    • Metformin plus PEX168 200 μg (n=175).
  • The treatment period lasted 24 weeks, followed by a 28-week extension phase.
  • Primary outcome was change in HbA1c at the end of the 24-week treatment period.
  • Funding: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Key results

  • Significant reductions in HbA1c from baseline to week 24 were observed in the PEX168 100 µg (1.16%±1.11%, P<.001 and pex168 p groups.>
  • At week 24, a higher proportion of patients who achieved an HbA1c
  • Researchers observed sustained reductions in HbA1c to week 52 with PEX168 100 µg (8.5%±0.89% to 7.7%±1.15%, P<.001 and pex168 to p>
  • Mild gastrointestinal events were reported. 

Limitations

  • Relatively short follow-up duration.